10-K · March 25, 2026
Paysign, Inc. demonstrated significant growth in 2025 with total revenues increasing by 40.5% year-over-year, reaching approximately $82 million, driven by expansions in pharma and plasma businesses. The acquisition of…
Earnings analysis · 10-Q
PAYS earnings analysis
Filed May 13, 2026 · Our reading of the company's report
The latest report
Paysign, Inc. reported Q1 2026 revenues of $28.04 million, a substantial 50.8% increase year-over-year, driven by strong growth in pharma and plasma segments. EPS stood at $0.02, slightly below expectations due to…
Read full summary
Paysign, Inc. reported Q1 2026 revenues of $28.04 million, a substantial 50.8% increase year-over-year, driven by strong growth in pharma and plasma segments. EPS stood at $0.02, slightly below expectations due to increased operating costs. Management remains optimistic about continued growth and has reaffirmed their full year guidance for 2026.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.02
What stood out
-
Revenue Growth of 50.8% YoY
Total revenue for Q1 2026 was $28.04 million, up from $18.60 million in Q1 2025.
-
Strong Performance in Pharma Segment
Pharma revenue increased 81.9% to $15.68 million, up from $8.62 million.
-
Significant Operating Income Improvement
Income from operations surged 167.9% to $6.67 million compared to $2.49 million.
-
Enhanced Gross Margin
Gross margin improved to 65.0%, up from 62.9% year-over-year.
-
Increased Cash Position
Available cash on hand reached $20.55 million, an increase of $13.70 million from Q1 2025.
-
Positive Operating Cash Flow
Net cash provided by operating activities was $18.79 million, compared to a cash outflow of $6.03 million in Q1 2025.
What to watch
-
EPS Misses Expectations
Actual EPS was $0.02, below the estimated $0.03.
-
Rising Operating Costs
Operating expenses increased by 25.5%, reaching $11.55 million compared to $9.20 million in the previous year.
-
Dependence on Market Conditions
Continued market pressure may affect operational cost management and revenues from new programs.
Management's outlook
Management reaffirmed full-year 2026 revenue and EPS guidance, citing expected balanced contributions from the plasma and pharma sectors.
Earlier filings 4
10-Q · November 13, 2025
Paysign, Inc. reported significant revenue growth of 41.6% year-over-year in Q3 2025, reaching $21.6 million. Both gross and operating margins were slightly lower compared to the previous year, though net income saw a…
10-Q · August 6, 2025
Paysign, Inc. reported strong revenue growth of 33.1% year-over-year in Q2 2025, totaling $19.08 million, driven primarily by a significant increase in pharma revenue. However, diluted EPS decreased to $0.02 from $0.01…
10-Q · May 9, 2025
Paysign, Inc. reported a strong Q1 2025 with total revenues of $18.6 million, up 41.0% year-over-year, driven mainly by a significant increase in pharma revenue. However, the diluted EPS decreased slightly to $0.02…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.